Vascular Concepts Limited
Developer and manufacturer of minimally invasive cardiovascular devices including coronary and peripheral stents, drug-coated balloons, balloon catheters, intracardiac occluders and a self‑expanding transcatheter aortic valve system. The company conducts device R&D and preclinical testing, sponsors and runs clinical registries and randomized trials, pursues regulatory approvals across multiple jurisdictions and supplies devices and procedural accessories to hospitals and health systems.
Industries
Nr. of Employees
medium (51-250)
Vascular Concepts Limited
Sahajanand Estate, Wakhariawadi, Near Dabholi, Ved Road, Surat 395 004, Gujarat, India
Products
Self‑expanding transcatheter aortic valve system (recapturable)
A self‑expanding, recapturable transcatheter aortic valve platform with supra‑annular bovine pericardial leaflets and delivery catheter featuring integrated sheath diameters for smaller access.
Coronary drug‑eluting stent systems with biodegradable polymer coatings
Coronary stent platforms engineered for deliverability and radial support combined with multilayer biodegradable polymer coatings to elute antiproliferative drugs with controlled kinetics.
Coronary stent with hydrophilic‑hydrophobic polymer matrix (everolimus eluting)
Stent platform using a multilayer biodegradable polymer matrix to provide biphasic elution of everolimus and improve coating integrity and flexibility.
Non‑compliant and semi‑compliant PTCA balloon catheters (low tip profile)
PTCA balloon catheters with multi‑layer polyamide balloons, tri‑fold rewrap, selective hydrophilic coating and low tip entry profiles for vessel preparation and angioplasty.
Drug‑coated peripheral balloon (paclitaxel DCB)
Peripheral balloon with proprietary coating process and paclitaxel drug load specified to achieve tissue drug retention and uniform coating, with SEM characterisation of surface morphology.
Intracardiac occluder devices (nitinol double‑disc)
Self‑expanding nitinol occluders with fabric fill and ultrathin metal nanocoating intended for closure of septal and ductal defects with recapture and redeploy capability.
Self‑expanding transcatheter aortic valve system (recapturable)
A self‑expanding, recapturable transcatheter aortic valve platform with supra‑annular bovine pericardial leaflets and delivery catheter featuring integrated sheath diameters for smaller access.
Coronary drug‑eluting stent systems with biodegradable polymer coatings
Coronary stent platforms engineered for deliverability and radial support combined with multilayer biodegradable polymer coatings to elute antiproliferative drugs with controlled kinetics.
Coronary stent with hydrophilic‑hydrophobic polymer matrix (everolimus eluting)
Stent platform using a multilayer biodegradable polymer matrix to provide biphasic elution of everolimus and improve coating integrity and flexibility.
Non‑compliant and semi‑compliant PTCA balloon catheters (low tip profile)
PTCA balloon catheters with multi‑layer polyamide balloons, tri‑fold rewrap, selective hydrophilic coating and low tip entry profiles for vessel preparation and angioplasty.
Drug‑coated peripheral balloon (paclitaxel DCB)
Peripheral balloon with proprietary coating process and paclitaxel drug load specified to achieve tissue drug retention and uniform coating, with SEM characterisation of surface morphology.
Intracardiac occluder devices (nitinol double‑disc)
Self‑expanding nitinol occluders with fabric fill and ultrathin metal nanocoating intended for closure of septal and ductal defects with recapture and redeploy capability.
Services
Operational support and sponsorship for randomized controlled trials and multicentre registries to evaluate device safety and effectiveness, including patient enrolment and data generation for publications and regulatory submissions.
Production and supply of stent systems, balloon catheters, drug‑coated balloons, occluders, transcatheter valve systems and procedural accessories for hospitals, distributors and health systems.
Operational support and sponsorship for randomized controlled trials and multicentre registries to evaluate device safety and effectiveness, including patient enrolment and data generation for publications and regulatory submissions.
Production and supply of stent systems, balloon catheters, drug‑coated balloons, occluders, transcatheter valve systems and procedural accessories for hospitals, distributors and health systems.
Expertise Areas
- Interventional cardiology device development (stents, balloons, catheters)
- Structural heart device and transcatheter valve development
- Drug‑eluting device coating and drug‑release engineering
- Drug‑coated balloon (DCB) coating and peripheral intervention devices
Key Technologies
- Biodegradable polymer coatings (PLLA, PLCL, PVP)
- Controlled drug‑release formulations (sirolimus, everolimus, paclitaxel)
- Drug‑coated balloon (DCB) coating and transfer technologies
- Nitinol frame devices with ultrathin metal nanocoatings
News & Updates
Transcatheter aortic valve system received CE mark and was launched in multiple regions (press coverage and press releases).
Regulatory approval from TGA Australia for a coronary stent platform.
Randomized and registry trial results for coronary stent platforms and transcatheter valve systems reported and published in peer‑reviewed journals.
Company announced completion of patient enrolment for a clinical trial.
Acquisition of a structural heart company to expand into transcatheter heart valve development and manufacturing.
Registry results for a coronary stent platform reported in BMJ Open.
Transcatheter aortic valve system received CE mark and was launched in multiple regions (press coverage and press releases).
Regulatory approval from TGA Australia for a coronary stent platform.
Randomized and registry trial results for coronary stent platforms and transcatheter valve systems reported and published in peer‑reviewed journals.
Company announced completion of patient enrolment for a clinical trial.
Acquisition of a structural heart company to expand into transcatheter heart valve development and manufacturing.
Registry results for a coronary stent platform reported in BMJ Open.